Retraction: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer (Cancer Res (2018) 69 (5575–5583) DOI: 10.1158/0008-5472.CAN-08-4235);Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer

Cancer Research

Volumn 69, Issue 13, 2009, Pages 5575-5583

  Banerjee, Sanjeev ^a   Kaseb, Ahmed O ^b   Wang, Zhiwei ^a   Kong, Deujan ^a   Mohammad, Mussop ^a   Padhye, Subhash ^a   Sarkar, Fazlul H ^a   Mohammad, Ramzi M ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HWCRC Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLOOXYGENASE 2; CYTOCHROME C; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; PROSTAGLANDIN E2; PROTEIN BCL 2; SURVIVIN; THYMOQUINONE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPSY; CANCER CELL; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; ELECTROPHORESIS; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCID MOUSE; TREATMENT DURATION; WESTERN BLOTTING;

EID: 67650466020     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-18-1174     Document Type: Erratum

References (43)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
2. Lage H, Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 2002;128:349-57.
3. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243-51.
4. Zalatnai A, Molnar J. Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 2007;21:339-47.
5. Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005;65:9064-72.
6. Banerjee S, Zhang Y, Wang Z, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer 2007;120:906-17.
7. Das KC, White CW. Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997;272:14914-20.
8. Chuang SE, Yeh PY, Lu YS, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-κB (NF-κB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002;63:1709-16.
9. Sarkar FH, Li Y. NF-κB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008;13:2950-9.
10. Sarkar FH, Li YW. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 2007;28:1305-15.
11. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here to eternity - the secret of pharaohs: therapeutic potential of black cumin seeds and beyond. Cancer Ther 2008;6:495-510.
12. Norwood AA, Tan M, May M, Tucci M, Benghuzzi H. Comparison of potential chemotherapeutic agents, 5-fluoruracil, green tea, and thymoquinone on colon cancer cells. Biomed Sci Instrum 2006;42:350-6.
13. Gali-Muhtasib H, Kuester D, Mawrin C, et al. Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 2008;68:5609-18.
14. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. Int J Oncol 2003;22:107-13.
15. Wilson-Simpson F, Vance S, Benghuzzi H. Physiological responses of ES-2 ovarian cell line following administration of epigallocatechin-3-gallate (EGCG), thymoquinone (TQ), and selenium (SE). Biomed Sci Instrum 2007;43:378-83.
16. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 2005;117:409-17.
17. Roepke M, Diestel A, Bajbouj K, et al. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells. Cancer Biol Ther 2007;6:160-9.
18. Rooney S, Ryan MF. Effects of α-hederin and thymoquinone, constituents of Nigella sativa, on human cancer cell lines. Anticancer Res 2005;25:2199-204.
19. Kaseb AO, Chinnakannu K, Chen D, et al. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 2007;67:7782-8.
20. Yi T, Cho SG, Yi Z, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 2008;7:1789-96.
21. Sethi G, Ahn KS, Aggarwal BB. Targeting nuclear factor-κB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 2008;6:1059-70.
22. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007;34:347-53.
23. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: advances to date and future directions. Drugs 2006;66:1059-72.
24. Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol 2007;34:S25-30.
25. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007;7:599-608.
26. Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH. Apoptosis-inducing effect of erlotinib is potentiated by 3,3′- diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther 2008;7:1708-19.
27. el-Rayes BF, Shields AF, Vaitkevicius V, Philip PA. Developments in the systemic therapy of pancreatic cancer. Cancer Invest 2003;21:73-86.
28. Sarkar FH, Li Y, Wang Z, Kong D. NF-κB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008;27:293-319.
29. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2007;224:326-36.
30. Bai J, Sui J, Demirjian A, Vollmer CM, Jr., Marasco 3W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005;65:2344-52.
31. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
32. Lee MA, Park GS, Lee HJ, et al. Survivin expression and its clinical significance in pancreatic cancer. BMC Cancer 2005;5:127.
33. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
34. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
35. Liu WS, Yan HJ, Qin RY, et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009;54:89-96.
36. Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
37. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
38. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 2005;92:271-7.
39. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5.
40. Albazaz R, Verbeke CS, Rahman SH, McMahon MJ. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 2005;5:361-9.
41. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
42. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003;2:1-7.
43. El Mezayen R, El Gazzar M, Nicolls MR, Marecki JC, Dreskin SC, Nomiyama H. Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett 2006;106:72-81.